Article citationsMore>>

Heiss, G., Wallace, R., Anderson, G.L., Aragaki, A., Bere- sford, S.A., Brzyski, R., Chlebowski, R.T., Gass, M., LaCroix, A., Manson, J.E., Prentice, R.L., Rossouw, J. and Stefanick, M.L. (2008) Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA, 299(9), 1036-1045.

has been cited by the following article:

• TITLE: Changing trends in colorectal cancer: possible cause and clinical implications

  AUTHORS: Mikhail Fisher, Leon Fisher, Bruce Waxman, Alexander A. Fisher

  KEYWORDS: Colorectal Cancer; Age; Gender; Hormone Replacement Therapy; Trends

  JOURNAL NAME: Health, Vol.2 No.8, August 25, 2010

  ABSTRACT: OBJECTIVES: The aims of this study were to determine whether pattern of patients presenting with colorectal cancer (CRC) in the last few years differs significantly from that previously reported in Australia, and to relate the trends, if present, to use of hormone replacement therapy (HRT). METHODS: We examined demographic and pathological characteristics of 145 consecutive CRC patients (65 females) treated in our institution in calendar years 2006-2007. Comparisons were made with data on 12536 CRC patients obtained from the Australian Association on Cancer Registries (AACR) for the year 2003, most recent available. Prescribing data for HRT were obtained from the Australian Commonwealth Department of Health and Ageing. RESULTS: The distribution of colon, sigmoid and rectal cancers in our series was 40%, 24.8% and 35.2%, respectively, which differs significantly from 65%, 8.1% and 26.9% in the AACR data (p